CASI Pharmaceuticals Net income (Q3, 2018)-8.8 M

CASI Pharmaceuticals Cash, 30-Sep-201898.9 M

CASI Pharmaceuticals EV205.9 M

USD | FY, 2013 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|

## Revenue | 23.7k | 47.7k | ||||

| (100%) | 101% | ||||

## Cost of goods sold | 7.5k | 6.3k | ||||

## Gross profit | 16.3k | 41.4k | ||||

| 69% | 87% | ||||

## R&D expense | 2.7m | 2.8m | 4.1m | 4.6m | 7.6m | |

## General and administrative expense | 3.0m | 3.8m | 3.1m | 4.8m | 3.2m | |

## Operating expense total | 5.7m | 26.2m | 7.2m | 9.4m | 10.8m | |

## EBIT | (5.7m) | |||||

## Interest expense | 26.6k | 81.5k | 26.1k | |||

## Net Income | (5.7m) | (5.7m) | (26.2m) | (7.2m) | (9.5m) | (10.8m) |

- Source: SEC Filings

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cost of goods sold | 6.3k | 2.7k | ||||||||||||||

## R&D expense | 793.8k | 560.0k | 724.5k | 697.0k | 865.0k | 1.2m | 942.3k | 1.0m | 1.4m | 1.0m | 1.0m | 1.7m | 971.0k | 1.7m | 1.7m | 1.8m |

## General and administrative expense | 648.7k | 891.4k | 891.9k | 1.2m | 924.8k | 857.6k | 673.9k | 765.1k | 1.9m | 676.9k | 644.2k | 691.4k | 625.9k | 1.3m | 4.0m | 6.9m |

## Operating expense total | 1.4m | 1.5m | 1.6m | 1.8m | 1.8m | 2.1m | 1.6m | 1.8m | 3.3m | 1.7m | 1.7m | 2.4m | 1.6m | 3.0m | 8.8m | 8.7m |

## Depreciation and amortization | 69.4k | |||||||||||||||

## Interest expense | 24.2k | 24.3k | 24.3k | 8.8k | 8.8k | 5.6k | 546.0 | |||||||||

## Interest income | 384.0 | 129.0 | 6.7k | |||||||||||||

## Net Income | (1.4m) | (1.5m) | (1.6m) | (21.5m) | (1.8m) | (2.1m) | (1.6m) | (1.8m) | (3.3m) | (1.7m) | (1.7m) | (2.4m) | (1.6m) | (3.6m) | (5.9m) | (8.8m) |

- Source: SEC Filings

USD | Y, 2009 | Y, 2010 | Y, 2011 | Y, 2012 | FY, 2013 | Y, 2013 | Y, 2014 | Y, 2015 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 6.3m | 4.9m | 1.1m | 8.0m | 15.1m | 15.1m | 10.7m | 5.1m | 5.1m | 27.1m | 43.5m |

## Accounts Receivable | |||||||||||

## Inventories | |||||||||||

## Current Assets | 15.4m | 15.4m | 11.0m | 5.6m | 5.6m | 27.4m | 43.8m | ||||

## PP&E | 78.1k | 78.1k | 261.8k | 218.8k | 218.8k | 229.6k | 1.0m | ||||

## Total Assets | 15.5m | 15.5m | 11.3m | 5.8m | 5.8m | 27.7m | 45.1m | ||||

## Accounts Payable | 402.5k | 402.5k | 754.6k | 884.1k | 884.1k | 1.1m | 2.1m | ||||

## Short-term debt | 1.5m | 1.5m | |||||||||

## Current Liabilities | 565.2k | 565.2k | 919.0k | 1.1m | 1.1m | 1.3m | 5.1m | ||||

## Long-term debt | |||||||||||

## Total Debt | 1.5m | 1.5m | |||||||||

## Total Liabilities | 11.9m | 6.9m | 6.6m | ||||||||

## Additional Paid-in Capital | 421.8m | 421.8m | 432.6m | 434.1m | 434.1m | 470.1m | 498.6m | ||||

## Retained Earnings | (399.1m) | (399.1m) | (425.3m) | (432.5m) | (432.5m) | (441.9m) | (452.7m) | ||||

## Total Equity | 14.9m | 14.9m | (422.2k) | (6.1m) | 20.8m | 38.5m | |||||

## Shares Outstanding | 28.6m | 32.4m | |||||||||

## Financial Leverage | 1 x | 1 x | -26.8 x | -1 x | 1.3 x | 1.2 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Net Income | (5.7m) | (26.2m) | (7.2m) | (9.5m) | (10.8m) |

## Depreciation and Amortization | 17.4k | 48.2k | 68.4k | 66.5k | 117.8k |

## Accounts Receivable | 669.3k | (23.7k) | 23.7k | ||

## Inventories | |||||

## Accounts Payable | (102.4k) | 352.2k | 129.5k | 180.5k | 849.4k |

## Cash From Operating Activities | (3.3m) | (4.0m) | (5.5m) | (6.0m) | (6.4m) |

## Purchases of PP&E | (934.7k) | ||||

## Cash From Investing Activities | (43.0k) | (466.3k) | (25.4k) | (64.8k) | (934.7k) |

## Cash From Financing Activities | 10.4m | 28.0m | 23.7m | ||

## Interest Paid | 7.5k |

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (4.4m) | (1.5m) | (3.1m) | (24.6m) | (1.8m) | (3.9m) | (5.5m) | (1.8m) | (5.1m) | (6.8m) | (1.7m) | (4.1m) | (5.7m) | (3.6m) | (9.5m) | (18.2m) |

## Depreciation and Amortization | 12.9k | 6.5k | 19.2k | 32.7k | 33.2k | 50.8k | 19.0k | 32.5k | 48.0k | 18.5k | 37.9k | 69.4k | 65.8k | 141.7k | 249.7k | |

## Accounts Receivable | 669.3k | (267.0) | 23.7k | |||||||||||||

## Accounts Payable | (152.6k) | 189.3k | 171.1k | 197.8k | 994.9k | 214.4k | 46.6k | (100.8k) | 61.7k | 34.8k | 55.4k | 118.6k | 139.3k | (522.3k) | 4.3k | (326.5k) |

## Cash From Operating Activities | (2.6m) | (890.1k) | (1.9m) | (2.9m) | (2.7m) | (4.2m) | (1.4m) | (2.8m) | (4.4m) | (1.5m) | (3.5m) | (5.0m) | (5.4m) | (8.8m) | (12.9m) | |

## Purchases of PP&E | (155.1k) | (726.4k) | (861.7k) | |||||||||||||

## Cash From Investing Activities | (16.9k) | (42.1k) | (181.4k) | (419.6k) | (16.7k) | (23.7k) | 30.1k | 30.8k | (798.0) | (33.5k) | (256.8k) | (405.8k) | (19.3m) | (19.9m) | (20.0m) | |

## Cash From Financing Activities | 10.4m | 10.2m | 16.2m | 23.5m | 30.7m | 51.9m | 89.5m |

USD | Y, 2018 |
---|---|

## EV/CFO | -16 x |

## Financial Leverage | 1.1 x |

Report incorrect company information